Pacira Pharmaceuticals (PCRX) Posts Q4 Loss of 72c/Share

Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q4 EPS of ($0.72), $0.18 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $4.23 million versus the consensus estimate of $4.05 million.

For earnings history and earnings-related data on Pacira Pharmaceuticals (PCRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citigroup (C) Tops Q2 EPS by 42c
• First Bancorp to acquire First Carolina Bancshares for $166M
• Globavend revenue rises 8% but net loss widens in first half 2026